Clinical trial

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2021-09-01

PhasePHASE2

Study timeline

Study start (actual)2021-09-01Date precision: day

Registry last updated2026-01-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non Small Cell Lung Cancerunresolved

Interventions

TaletrectinibDRUG · verified · RxNorm: taletrectinib

Sponsors & collaborators

Nuvation Bio Inc.lead sponsor

Mapped research locations

MadridSpain4 BarcelonaSpain4 MilanItaly4 SeoulSouth Korea2 ValenciaSpain2 TokyoJapan2 Saint-HerblainFrance2 HoustonTexas, United States1 Los AngelesCalifornia, United States1 DallasTexas, United States1 TorontoOntario, Canada1 NashvilleTennessee, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04919811 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.